Development of Spray-Dried Cyclodextrin-Based Pediatric Anti-HIV Formulations
Date of Original Version
The human immunodeficiency virus (HIV) impacts up to 37 million people globally, of which 1.8 million are children. To date, there is no cure for HIV, although treatment options such as antiretroviral therapy (ART) are available. ART, which involves a patient taking a combination of antiretrovirals, is being used to treat HIV clinically. Despite the effectiveness of ART, there is currently no palatable pediatric formulation to treat HIV in children, which has hindered patient compliance and overall treatment efficacy. In addition, anti-HIV therapeutics are often poorly water-soluble, and hence have poor bioavailability. In the present study, we developed a pediatric-friendly formulation for anti-HIV therapeutics with improved dissolution characteristics of the therapeutic agents. Lopinavir (LPV) and ritonavir (RTV), available as FDA-approved fixed-dose combination products, were chosen as model ART drugs, and the formulation and processing parameters of spray-dried cyclodextrin (CD)-based LPV and RTV complexes were studied. Results showed that the spray-dried complexes exhibited enhanced dissolution profiles in comparison to pure drugs, particularly spray-dried β-CD complexes, which showed the most favorable dissolution profiles. This current formulation with enhanced dissolution and taste-masking ability through the use of cyclodextrin has the potential to address the unmet need for the development of suitable pediatric formulations. Graphical abstract: [Figure not available: see fulltext.]
Publication Title, e.g., Journal
Ivone, Ryan, Ashvin Fernando, Brenton DeBoef, Samantha A. Meenach, and Jie Shen. "Development of Spray-Dried Cyclodextrin-Based Pediatric Anti-HIV Formulations." AAPS PharmSciTech 22, 5 (2021). doi: 10.1208/s12249-021-02068-w.